<DOC>
	<DOCNO>NCT01385631</DOCNO>
	<brief_summary>The purpose study examine effect cholesterol lower agent Ezetimibe use addition optimal treatment Atorvastatin patient acute ST-Elevation Myocardial Infarction ( STEMI ) prior statin therapy . An area arteriosclerosis demand intervention coronary vessel infarct relate use measure point examine time infarction 12 month use intravascular ultrasound optical coherence tomography . At time technique use examine implant stent .</brief_summary>
	<brief_title>Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction .</brief_title>
	<detailed_description>Optical coherence tomography ( OCT ) intravascular ultrasound ( IVUS ) tissue characterization ( IVUS-TC ) relatively new expansion intravascular assessment , capacity ass plaque composition , potentially , identify vulnerable plaque . One mechanism statins improve patient outcome may change composition `` vulnerable '' plaque . The main effect believe rely lower LDL-c . The question whether reduction LDL add ezetimibe optimal cholesterol lower therapy use statin may result plaque stabilization reduction . This hypothesis current study . 100 patient randomize Ezetimibe 10 mg per day placebo . All patient treat Atorvastatin 80 mg. OCT IVUS perform inclusion ( typically day Primary PCI ) follow-up 12 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>ST segment elevation acute myocardial infarction 20 % &lt; angiographic diameter stenosis &lt; 50 % previously revascularized native coronary artery Statin na√Øve In fertile woman : Ongoing contraception IUD hormonal contraception . Pharmacologic lipid lower treatment index hospitalization Atrial fibrillation , well ratecontrolled Ventricle frequency variation factor 2 1 minute Unconscious patient History statin induce myopathy , serious hypersensitivity reaction HMGCoA reductase inhibitor ( statin ) include Atorvastatin . Pregnant woman , woman breast feeding , woman childbearing potential use chemical mechanical contraception positive serum pregnancy test ( serumhuman chorionic gonadotrophin [ BetaHCG ] analysis ) History malignancy ( unless document disease free period exceed 5years present ) exception basal cell squamous cell carcinoma skin . Women history cervical dysplasia would permit enter study provide 3 consecutive clear Papanicolaou ( Pap ) smear Uncontrolled hypothyroidism ( TSH &gt; 1.5xULN ) Abnormal LFT 's History alcohol drug abuse within last 5 year ( may affect compliance ) Current active liver disease ( ALT/SGPT &gt; 2xULN severe hepatic impairment ( protect patient safety direct label currently approve statin ) Unexplained creatine kinase ( CK &gt; 3xULN ) ( To protect patient safety ) ( increase baseline acute ST segment elevation myocardial infarction day enrolment ) Serum creatinine &gt; 176mmol/L ( 2.0mg/dL ) ( unless protocol specifically aim investigate chronic renal disease population ) Participation another investigational drug study le 4 week enrolment study , accord subject local ethic committee requirement large period stipulate ( avoid potential misinterpretation overlap adverse event ) Treatments cyclosporine Treatment gemfibrozil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>ST-Segment Elevation Myocardial Infarction</keyword>
	<keyword>Intravascular ultrasound</keyword>
	<keyword>IVUS</keyword>
	<keyword>Optical coherence tomography</keyword>
	<keyword>OCT</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Randomized trial</keyword>
	<keyword>Hypolipidemic Agents</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Lipid Regulating Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>